All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

KarMMa-9: Idecabtagene vicleucel plus lenalidomide for the treatment of NDMM with suboptimal response to ASCT

Jun 4, 2024
Learning objective: After reading this article, readers will be able to cite a new clinical development in newly diagnosed multiple myeloma

Bookmark this article

Patients with newly diagnosed multiple myeloma (NDMM) who experience an incomplete response to autologous stem cell transplantation (ASCT) have poorer outcomes, with an increased risk of progression (38%) and an increased risk of death (41%) compared with patients who experience a complete response.1 KarMMa-9 (NCT06045806) is an ongoing phase III trial comparing the efficacy and safety of idecabtagene vicleucel (ide-cel) plus lenalidomide for maintenance vs lenalidomide alone in patients with NDMM who had a suboptimal response (partial response or very good partial response) to ASCT.

Here we summarize a poster presentation by Mateos, et al.1 from the 5th European Myeloma Network Meeting, 2024, on the rationale and study design of the phase III KarMMa-9 trial.1

Study design and key findings1

  • KarMMa-9 is an ongoing multicenter, randomized trial, currently enrolling across 19 countries.
  • Eligibility criteria include:
    • Patients with NDMM
    • Aged 18 years
    • East Cooperative Oncology Group (ECOG) performance status of 0–2
    • Received 4–6 cycles of induction therapy
    • Single ASCT 80–120 days prior to study treatment
    • ‘Partial response’ or ‘very good partial response’ post-ASCT at the time of consent
    • No prior maintenance after ASCT
  • The primary endpoint is progression-free survival (PFS) per the independent review committee (IRC).
  • The key secondary endpoint is overall survival (OS) The other secondary endpoints include measurable residual disease-negative complete response rate, event-free survival, duration of response, complete response rate per IRC, time to progression per IRC, PFS2, time to next treatment, safety, health-related quality of life, and pharmacokinetics.
  • Key safety outcomes include AE reporting.
  • Patients will be randomly assigned to receive ide-cel plus lenalidomide or standard-of-care lenalidomide maintenance (Figure 1).
    • Combining ide-cel with standard-of-care maintenance therapy is expected to improve clinical outcomes and extend PFS in patients with clinically high-risk NDMM.
  • Randomization will be stratified, based on the stage of disease, induction therapy, and the degree of treatment response post-ASCT.

Figure 1. KarMMa-9 study design*

CAR, chimeric antigen receptor; ide-cel, idecabtagene vicleucel; LDC, lymphodepleting chemotherapy; OS, overall survival; PD, progressive disease; PFS, progression-free survival.
*Adapted from Mateos, et al.1
Apheresis to be performed within 14−42 days after last dose of R.
Fludarabine 30 mg/m2 and cyclophosphamide 300 mg/m2 on Days -5, -4, and -3 prior to ide-cel infusion.

  • The trial was initiated in October 2023 and is currently recruiting at 118 sites in 19 countries.
    • Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Greece, Israel, Italy, Japan, Korea, Norway, Poland, Romania, Spain, United Kingdom, and the USA
  • A total of 618 eligible patients with NDMM have been enrolled so far.

Key learnings1

  • KarMMa-9 trial will compare the efficacy and safety of ide-cel and lenalidomide as a combination therapy vs lenalidomide alone in patients with NDMM who experience an incomplete response to ASCT.
  • Ide-cel combined with standard-of-care maintenance therapy is expected to improve clinical outcomes and prolong PFS in this high-risk population.

  1. Mateos MV, Cohen A, Harrison S, et al. Efficacy and safety of idecabtagene vicleucel with lenalidomide maintenance versus lenalidomide maintenance alone in adult patients with newly diagnosed multiple myeloma who have suboptimal response to autologous stem cell transplantation: phase 3 KarMMa-9 trial. Poster presentation #P-16. 5th European Myeloma Network; April 18–20, 2024; Turin, Italy.


Subscribe to get the best content related to multiple myeloma delivered to your inbox